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Modeling the Kinetics of Serum Glial Fibrillary Acidic Protein,
Ubiquitin Carboxyl-Terminal Hydrolase-L1, and S100B
Concentrations in Patients with Traumatic Brain Injury
Robert D. Welch,1,2 Morgan Ellis,1 Lawrence M. Lewis,3 Syed I. Ayaz,1
Valerie H. Mika,1 Scott Millis,1,4 and Linda Papa5
Abstract
Glial fibrillary acidic protein (GFAP), ubiquitin carboxyl-terminal hydrolase-L1 (UCH-L1), and S100B have been shown
to be predictive of patients with brain injury. Kinetics of these biomarkers in injured humans have not been extensively
examined. This prospective multi-center study included patients with mild-to-moderate traumatic brain injury. Blood
samples obtained at enrollment and every 6 h up to 24 h post-injury were assayed for GFAP, UCH-L1, and S100B.
Random effects models examined changes in the biomarkers’ level over time. A total of 167 patients were enrolled; mean
age was 46.0 – 17.8, 61.1% were male, 143 (85.6%) had a Glasgow Coma Scale score of 15, and 33 (19.8%) had a positive
head computed tomography (CT) scan. Baseline median biomarker concentrations for all three were higher among
CT-positive patients ( p < 0.0001) but GFAP was the only biomarker that significantly increased over time among CT-
positive patients relative to CT-negative patients (log transformed values 0.037; 95% confidence interval 0.02, 0.05;
p < 0.001), indicating a 3.7% per hour rise in GFAP concentration. There was no significant increase in either UCH-L1 or
S100B in CT-positive patients ( p = 0.15 and p = 0.47, respectively). GFAP concentrations increased 3.7% per hour among
CT-positive patients whereas neither UCH-L1 nor S100B increased, compared with CT-negative patients. The kinetics
and temporal profile of GFAP suggest it may be a more robust biomarker to detect patients with positive CT findings,
particularly at later post-injury times. Further study is needed to determine if GFAP is a useful test to follow throughout a
patient’s clinical course.
Keywords: biomarkers; glia cell response to injury; neural injury; traumatic brain injury
Introduction
Over the past decade, the number of traumatic brain injury(TBI)–related emergency department (ED) visits, hospital-
izations, and deaths have increased in the United States, making
TBI a serious public health concern as well as a leading cause of
morbidity and mortality.1 Despite the availability of clinical de-
cision rules,2,3 increasing pressure to deliver cost-effective care,
and the controversy regarding potentially hazardous ionizing ra-
diation exposure,4,5 computed tomography (CT) remains a fre-
quently used but often uninformative diagnostic test for patients
presenting to the ED with mild-to-moderate TBI (mmTBI).6 In an
attempt to reduce CT use in mmTBI, numerous studies have
evaluated the diagnostic significance of serum biomarkers, which
are released as a result of head trauma and may potentially predict
the presence of brain injury.7,8
Among the most widely studied biomarkers for this purpose are
S100B,9,10 a protein involved in intracellular regulation that is
expressed in astroglia cells,11 and glial fibrillary acidic protein
(GFAP),12 a cytoskeletal protein expressed in astroglia cells, as
well.11 Although several studies have reported the diagnostic value
of S100B13,14 and GFAP as biomarkers for mmTBI,15,16 to date
there remains insufficient evidence to warrant reliance on either as
a screening tool to determine the need for head CT in the U.S.10,17
However, recent work has suggested low serum levels of the less-
studied biomarker ubiquitin carboxyl-terminal hydrolase-L1
(UCH-L1), a neuron-specific deubiquitinase, obtained within 6 h of
injury have better early diagnostic utility in screening for and ex-
cluding acute intracranial lesions found on head CT scans in adult
patients with mmTBI than either S100B or GFAP.18
While this suggests a singular, more sensitive threshold value of
UCH-L1 may be sufficient to define a negative head CT scan early
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after injury, there is limited data regarding the temporal profiles of
serum UCH-L1 and GFAP in patients with mmTBI. Prior work in
an animal model of moderate TBI determined that the time window
of GFAP to detect acute brain injury following TBI was wider than
UCH-L1,19 suggesting GFAP may be the more robust biomarker
for mmTBI beyond the acute post-injury phase. This finding is
consistent with a recent study (2016) in humans, which demon-
strated serum UCH-L1 levels rose early after mmTBI, peaked at
8 h, then rapidly declined, whereas GFAP peaked later (20 h), and
declined gradually thereafter but remained elevated over a 7-day
period. Further, serum GFAP concentrations obtained across 7 days
were consistent in their ability to detect CT lesions and the need for
neurosurgical intervention.20 Given that serum concentration of
UCH-L1 may be useful in the evaluation of patients with suspected
mmTBI in the acute post-injury phase and that GFAP levels rise
later and remain elevated longer, we sought to 1) further charac-
terize the kinetics of these biomarkers and 2) examine the potential
use of determining both biomarker levels during the 24-h post-
injury period when evaluating the need for CT use and hospital
admission for patients with suspected mmTBI.
The goal of this study was to determine the association of CT
findings with serum levels of GFAP, UCH-L1, and S100B mea-
sured repeatedly over 24 h among patients with suspected mmTBI.
In particular, the main interest was to determine potential differ-
ences in the biomarkers’ kinetics among CT-positive and CT-
negative patients and to assess their potential clinical application
during the initial 24 h after injury.
Methods
Patients and study procedures
This secondary analysis of data derived from a prospective
multi-center observational study included patients 18–80 years of
age who presented at one of seven study site hospital EDs with a
blunt closed-head injury and were assessed for potential mmTBI.18
Study sites included both U.S. and European hospitals and were
composed of Level 1 and 2 trauma centers and a non-trauma center
(Table 1). Eligible patients were those with an initial Glasgow
Coma Score (GCS) of 9-15 (defined as mmTBI ) for whom an
emergency head CT scan was obtained for evaluation of head injury
as deemed necessary by the attending ED physician. All sites were
aware of and considered available clinical decision rules to guide
the need for imaging; however, no formal rules for obtaining a CT
were utilized so as to best reflect current practice in the U.S. and
Europe.
Included patients presented within 4 h of injury, received a CT
scan as part of routine care, and had the first blood sample obtained
for analysis within 6 h of injury. For this study, patients having only
one serum sample obtained for biomarker analysis were excluded.
In some instances, the first sample quantity obtained was inade-
quate for analysis but these patients were still included if they had at
least two subsequent adequate samples for analysis. Table 2 details
the inclusion and exclusion criteria. Institutional Review Board
approval was obtained at each study site and each site also obtained
approval by the ethics board of the U.S. Army Medical Research
and Materiel Command Office of Research Protections Human
Research Protection Office Department of Defense.
Baseline patient characteristics
Baseline patient data collected by trained research personnel
included demographics, medical history, substance use history,
GCS scores, loss of consciousness (LOC), and circumstances
Table 1. Description of Study Site Hospitals
Study site Location Annual ED volume Designation
Washington University, Barnes-Jewish Hospital St. Louis, MO 95,000 Level I
University of Florida, Shands Hospital Gainesville, FL 66,000 Level I
Gwinnett Medical Center - Lawrenceville Atlanta, GA 100,000 Level II
Dekalb Medical - North Decatur Atlanta, GA 92,000 Non-trauma
Wayne State - Detroit Receiving Hospital Detroit, MI 90,000 Level I
University of Pécs Medical Center Pecs, Hungary 25000O Level 1*
Albert Szent-Györgyi Medical Center - University of Szeged Szeged, Hungary 90,000 Level 1*
OThe ED volume is >25,000/year, and the facility cares for more than 2000 neurotrauma cases/year.
*This is equivalent to a Level I facility in the United States.
ED, emergency department.
Table 2. Inclusion/Exclusion Criteria
Inclusion criteria
 The subject was ‡18 years of age and £80 years of age.
 Acceleration or deceleration closed injury to the head that was
either self-reported or witnessed.
 Presented to an ED within 4 h of injury.
 An initial GCS score of 9-15 in the ED performed by PI or
trained study personnel.
 ED workup included a head CT scan (based on standard
practice and/or decision rules).
 Informed consent was obtained from the subject or his/her legal
representative; oral consent for the initial blood draw and/or
deferred consent to 24 h was allowed for patients who were
unable to consent at initial evaluation or exception from the
informed consent requirement by use of ‘‘community consent’’
if approved by an Institutional Review Board.
 The PI deemed the subject to be an appropriate study candidate.
Exclusion criteria
 Participation in another potentially confounding clinical study.
 Inability to accurately determine time of injury.
 Head CT not completed as part of clinical emergency care.
 Primary diagnosis of ischemic or hemorrhagic infarct.
 Not available for the 35-day follow-up visit.
 Venipuncture not feasible.
 Blood donation within 1 week of screening.
 The subject was otherwise determined medically unsuitable for
study participation
ED, emergency department; GCS, Glasgow Coma Scale; PI, principal
investigator; CT, computed tomography.















































related to the mechanism of injury. This was used to describe the
study patient’s general characteristics and injury patterns.
Serum sample and handling
Blood samples were collected at time of study enrollment and
every 6 h up to the time of discharge (either ED or hospital) or up to
24 h (maximum of five samples during index visit). Patients were
evaluated at follow up (Day 35 – 5 days) for neuropsychological
testing and to obtain another blood sample. The neuropsychological
testing was not part of this study’s outcome assessment and blood
Table 3. Analytical Performances of Each Biomarker
Biomarker S100B UCH-L1 GFAP
Limit of detection, pg/mL 5 10 20
Lower limit of quantification, pg/mL N/A 30 30
Intra-assay coefficient of variation, % 2.1 4.5 3.7
Inter-assay coefficient of variation, % 2.8 4.6 5.8
UCH-L1, ubiquitin carboxyl-terminal hydrolase-L1; GFAP, glial
fibrillary acidic protein; N/A, not available.
FIG. 1. Flow diagram describing excluded and included patients with mild-to-moderate traumatic brain injury. CT, computed
tomography; UCH-L1, ubiquitin carboxyl-terminal hydrolase-L1; GFAP, glial fibrillary acidic protein.















































Table 4. Patient Characteristics
CT negative CT positive All subjects
80.2% (total n = 134) 19.8% (total n = 33) (total n = 167)
Age (mean – SD) 43.8 – 17.3 55.2 – 16.8 46.0 – 17.8
Sex
Female 41.8% (56) 27.3% (9) 38.9% (65)
Male 58.2% (78) 72.7% (24) 61.1% (102)
Race
White 74.6% (100) 93.9% (31) 78.4% (131)
Black 20.9% (28) 0.0% (0) 16.8% (28)
Other 4.5% (6) 6.1% (2) 4.8% (8)
Employment status
Employed 49.2% (66) 39.4% (13) 47.3% (79)
Unemployed 20.1% (27) 15.1% (5) 15.2% (32)
Student 8.2% (11) 0.0% (0) 6.6% (11)
Homemaker 1.5% (2) 0.0% (0) 1.2% (2)
Retired 16.4% (22) 39.4% (13) 21.0% (35)
Alcohol
Yes 29.8% (40) 36.4% (12) 31.1% (52)
No 70.1% (94) 63.6% (21) 68.9% (115)
Drugs
Yes 13.4% (18) 3.0% (1) 11.4% (19)
No 86.6% (116) 97.0% (32) 88.6% (148)
Smoke
Yes 34.3% (46) 36.4% (12) 34.7% (58)
No 65.7% (88) 63.6% (21) 65.3% (109)
Mechanism of injury
MVC 41.8% (56) 12.1% (4) 35.9% (60)
Assault 8.2% (11) 12.1% (4) 9.0% (15)
Fall (n = 166) 55.6% (74) 78.8% (26) 60.2% (100)
Sports 4.5% (6) 0.0% (0) 3.6% (6)
LOC
Yes 73.1% (98) 72.7% (24) 73.0% (122)
No 26.9% (36) 27.3% (9) 26.9% (45)
LOC Information
Self-reported 38.1% (51) 27.3% (9) 35.9% (60)
Unknown 35.1% (47) 39.4% (13) 35.9 % (60)
Witnessed 26.9% (36) 33.3% (11) 28.1% (47)
GCS
15 90.3% (121) 66.7% (22) 85.6% (143)
14 7.5% (10) 18.2% (6) 9.6% (16)
13 0.75% (1) 9.1% (3) 2.4% (4)
9 to 12 1.5% (2) 6.1% (2) 2.4% (4)
Initial biomarker concentration (median; 25th, 75th; pg/mL)
GFAP 10 (4, 31) 122 (20, 437) 14 (5, 74)
UCH-L1 63 (27, 110) 132 (98, 235) 75 (32, 142)
S100B (n = 152) 110 (70, 240) 225 (180, 410) 120 (80, 270)
Number of biomarker determinations per patient
2 43.3% (58) 12.1% (4) 37.1% (62)
3 21.0% (28) 21.2% (7) 21.0% (35)
4 12.7% (17) 27.3% (9) 15.6% (26)
5 23.1% (31) 39.4% (13) 26.3% (44)
Number of patients with values below LOD
GFAP 66.4% (89) 21.2% (7) 57.5% (96)
UCH-L1 4.5% (6) 0.0% (0) 3.6% (6)
S100B (n = 145) N/A N/A N/A
Number of patients with values below LLQ
GFAP 73.1% (98) 27.3% (9) 64.1% (107)
UCH-L1 28.4% (38) 3.0% (1) 23.3% (39)
S100B (n = 145) N/A N/A N/A
(continued)















































samples were rarely obtained and therefore were not included in the
analysis and are not reported here. Blood samples were processed
and the resulting serum was stored at -80C and then shipped on
dry ice to a central repository for storage until time of testing as per
a pre-defined specimen handling procedure.
Serum analysis for GFAP, UCH-L1, and S100B
Serum samples were analyzed for UCH-L1 and GFAP concen-
tration by an enzyme-linked immunosorbent assay at a later time by
technicians blinded to clinical data and CT results. Samples were
run in triplicate and the mean used to determine the final concen-
tration. If one replicate was more than 4 standard deviations dif-
ferent from the mean of the other two replicates, the mean
concentration was determined using just the two replicates. Dupli-
cate and high and low positive controls were included with each
plate. Details of the assay procedure can be found elsewhere.18
UCH-L1 and GFAP tests were performed by Banyan Biomarker,
Inc. S100B concentrations were determined using an electro-
chemiluminescence immunoassay designed for in vitro diagnostic
testing (Roche, Cobas 6000). Results for S100B are reported in lg/L
with the standard normal reference intervals of 0.00-0.09 lg/L.
Although various cut-off values have been proposed, for the pur-
poses of this study an S100B ‡ 0.10 lg/L (100 pg/mL) was con-
sidered to be abnormal and could indicate a traumatic abnormality
on head CT.21,22 S100B samples were tested at Halland’s Hospital
Halmsead, Department of Clinical Chemistry, Halmstead, Sweden.
The lower limit of quantification (LLQ) for both UCH-L1 and
GFAP was 30 pg/mL (none provided for S100B), and the lower
limit of detection (LLD) for UCH-L1, GFAP, and S100B was
10 pg/mL, 20 pg/mL, and 5 pg/mL, respectively. Table 3 summa-
rizes these values and the intra-assay and inter-assay coefficients of
variation for each study serum biomarker. For this analysis, serum
concentrations above the LLD but less than or equal to the LLQ
were assigned the LLQ value (30 pg/mL for GFAP and UCH-L1;
no LLQ provided for S100B). Serum concentrations at or below the
LLD were assigned the value of the LLD (5 pg/mL for S100B,
10 pg/mL for UCH-L1, and 20 pg/mL for GFAP). There is no clear
standard or ideal method used to analyze values below the LLD
(left-truncated values). Some advocate eliminating those values,
others suggest imputing values, using a fraction of the LLD, a
Table 4. (Continued)
CT negative CT positive All subjects
80.2% (total n = 134) 19.8% (total n = 33) (total n = 167)
Number of biomarker samples during time intervals (n = 553)
0–6 h 48.9% (207) 39.2% (51) 46.6% (258)
> 6–12 h 23.2% (98) 18.5% (24) 22.1% (122)
>12–18 h 13.9% (59) 20.8% (27) 15.5% (86)
>18–24 h 13.9% (59) 21.5% (28) 15.7% (87)
CT, computed tomography; SD, standard deviation; MVC, motor vehicle collision; LOC, loss of consciousness; GCS, Glasgow Coma scale; GFAP, glial
fibrillary acidic protein; UCH-L1, ubiquitin carboxyl-terminal hydrolase-L1; LOD, level of detection; N/A, not available; LLQ, lower limit of quantification.
Table 5. Excluded Subjects
Subjects (total n = 97)
























9 to 12 0% (0)
Initial biomarker values (median; 25th, 75th; pg/mL)
GFAP 5 (0, 19)
UCH-L1 51 (21, 100)




SD, standard deviation; GCS, Glasgow Coma Scale; GFAP, glial
fibrillary acidic protein; UCH-L1, ubiquitin carboxyl-terminal hydrolase-
L1; CT, computed tomography.
Table 6. Definition of Acute Intracranial Lesion
Acute intracranial lesion is defined as any trauma induced
or related finding. Acute lesions may include the following
and the number of each finding:
N
Extra-axial lesions
Acute epidural hematoma 3












Dural venous sinus injury and/or thrombosis 0















































reverse Kaplan-Meier Estimator, or other techniques to determine a
final value.23–26 For this analysis, we chose not to eliminate the
values, use a fraction of the value, or use an imputation method, but
rather chose to ‘‘round-up’’ for a variety of reasons. The very low
values at the LOD and LLQ would not impact our results given the
larger variation and it was thought to be a more conservative ap-
proach when considering a change over time (less change from
baseline if values rise since we were not interested in small non-
clinically useful but statistically significant changes). Assay results
were not available to the treating clinician and were not used to
guide treatment. For this main analysis, we considered results for
all samples collected within 24 h after injury.
Head CT scans
Each subject’s head CT images were reviewed by an indepen-
dent committee consisting of three blinded board-certified neuro-
radiologists. The neuro-radiologists determined whether a CT scan
was positive, defined as the presence of an acute trauma-related
intracranial lesion. A charter outlining the criteria and procedures to
be followed for scoring the CT scans was developed prior to the
reading and interpretation of any of the CT images. Two of the
neuro-radiologists, who had no access to any other clinical or labo-
ratory data except subject age and gender, reviewed all of the study
subjects’ CT scans. Any discrepancy with respect to CT-positive or
CT-negative was adjudicated by a third blinded radiologist and in
those instances, was the final interpretation. Inter-rater reliability
between the two primary radiologists was determined using Cohen’s
kappa statistic.
Outcomes
For this study, the primary clinical outcome was the result of the
head CT scan (positive/negative) among patients with repeated
blood samples drawn over 24 h post-injury. The main outcomes of
interest, however, were the change in the three biomarkers’ values
over time among CT-positive and CT-negative patients.
Data analysis and reporting
A descriptive analysis for all subjects was performed. Patient
groups (CT positive and CT negative) were compared using pro-
portions and means or medians where appropriate. For selected
binomial proportions, the exact (Clopper-Pearson) 95% confidence
intervals (CIs) were provided. To compare biomarker values be-
tween CT-negative and CT-positive patients, the non-parametric
Wilcoxon rank-sum test was used.
Individual graphical displays of the three biomarkers’ serum
concentration over time were constructed—one for the patient’s
individual trend overlaid with a locally weighted scatter plot
FIG. 2A. Scatter plot with the locally weighted scatter plot smoothing regression lines demonstrating ubiquitin carboxyl-terminal
hydrolase-L1 (UCH-L1) values. ‘‘+’’ and ‘‘o’’ represent the biomarker value (Y-axis) concentration at the given time-point (X-axis).
CT, computed tomography.















































smoothing (LOESS) plots (with 95% confidence limits) and
another scatter plot that showed biomarker concentrations at
various time-points obtained post-injury (also overlaid with
LOESS plots). This was done to conceptualize the crude ki-
netics of each biomarker and provide a starting reference for
model development.
For this study, the main interest was association of the CT results
(positive or negative) with the change in each serum biomarker’s
concentrations measured up to 24 h post injury (CT*Time inter-
action) that was in addition to (independent of) other important
clinical factors. Since it was likely that study subjects would have
different initial biomarker concentrations (the baseline starting
point or intercept), different biomarker kinetics over time (slope)
and potentially correlated data due to the multiple samples ob-
tained, mixed linear models with random effects (intercept and
slope) were used for each of the three biomarkers. Given the dis-
tribution of biomarker values and model diagnostics, a natural log
transformation of the biomarkers’ values were utilized (lognormal
distribution in SAS PROC GLIMMIX). Based on prior information
and potentially theoretical importance, gender and presenting GCS
score were mandatorily included in each model. Other factors
considered for inclusion were age, race, LOC, and mechanism of
injury. The Log Likelihood ratio and Bayesian information crite-
rion tests were used to determine if non-mandatory variables should
be included in the model and the optimal covariance matrix for the
random effects.
Two sensitivity analyses were performed to examine results for
consistency. Since there is no consensus on how to handle serum
biomarker values below the LLQ and the LOD, the same models
were fit using the actual reported values, even when below the
detection limits. Some values were reported as 0 pg/mL and these
were re-coded to 1 pg/mL so that those values could be log
transformed for the models. Since it was likely that patients with a
GCS <15 would be imaged regardless of the initial biomarker
concentration (at least in the U.S.), we performed the main anal-
ysis again but included only patients with an initial GCS = 15. For
all model results, we reported the parameter estimates for the
transformed values with 95% CI. For the main results, we also
back-transformed the parameter estimate values and provide the
interpreted percent increase of each biomarker for the variable in
the main models.
Finally, we calculated the sensitivity and specificity for each
biomarker at various biomarker values using logistic regression
and plotted the areas under the receiver operating characteris-
tics curves (AUROCs) at 6-h intervals (0-6 h, 6-12 h, 12-18 h,
and 18-24 h) to determine diagnostic characteristics at these
various time intervals; however, one should note that this is
only exploratory and the derived AUROC cannot be considered
definitive. A p value of less than 0.05 was considered signifi-
cant. All data were analyzed using SAS version 9.4 (Carey,
NC) and published guidelines for statistical reporting were
adhered to.27
FIG. 2B. Scatter plot with the locally weighted scatter plot smoothing regression lines demonstrating glial fibrillary acidic protein
(GFAP) values. ‘‘+’’ and ‘‘o’’ represent the biomarker value (Y-axis) concentration at the given time-point (X-axis). CT, computed
tomography.

















































The study enrolled 290 patients: 26 were initially excluded for
a variety of reasons; thus, leaving a total of 264 patients who had
data for at least one blood sample and the required CT results. We
excluded patients with only one blood sample (n = 97), thus
leaving 167 patients included in this study. Fifteen of the 167
patients, however, were not tested for S100B since this part of the
study procedure was added after study initiation and/or some
subjects did not have enough blood obtained for analysis of all
three markers. This resulted in 152 patients with S100B data.
Figure 1 outlines the study patient selection process. Table 4
details the characteristics of included and excluded patients. Since
exclusion of patients with only one serum biomarker determina-
tion was likely not a random factor, no formal statistical tests were
used to define differences.
The mean age of all 167 patients was 46.0 – 17.8 years and
61.1% (95% CI 53.2% to 68.5%) were male. The main mecha-
nisms of injury were motor vehicle crashes and/or falls. There
were 143 of the total 167 patients (85.6%; 95% CI 79.4% to
90.6%) who had an initial GCS of 15 of which 22 (15.4%; 95% CI
9.9% to 22.4%) had a positive CT scan. Among patients with a
GCS <15 (n = 24), 11 (45.8%; 95% CI 25.5% to 67.2%) had a
positive CT scan. The initial serum concentration for each bio-
marker was higher among CT-positive patients ( p < 0.0001 for
UCH-L1, GFAP, and S100B). Table 5 details these and other
patient characteristics.
Head CT results
Of the 167 CT scans obtained, 126 were classified as neg-
ative by both primary radiologists, 29 were classified as posi-
tive by both primary radiologists, and 11 received discrepant
positive and negative classifications from the two primary ra-
diologists (one radiologist did not read one case; Kappa = 0.80;
95% CI 0.69 to 0.91). After the final adjudicated by a third
independent radiologist, 33 patients (19.8%; 95% CI 14.0% to
26.6%) had a scan that was positive for an acute traumatic
intracranial lesion. Table 6 lists the findings considered positive
and the number of patients with each specific finding. Since
some patients had more than one abnormality, the total adds up
to more than 33.
Biomarker samples
For the 167 study subjects, 553 samples were collected for both
UCH-LI and GFAP. Sixty-two patients had two samples obtained
prior to study termination and 105 patients had three or more
samples obtained during the 24-h study period. There were a total
of 278 serum samples available for S100B analysis from the 152
FIG. 2C. Scatter plot with the locally weighted scatter plot smoothing regression lines demonstrating S100B values. ‘‘+’’ and ‘‘o’’
represent the biomarker value (Y-axis) concentration at the given time-point (X-axis). CT, computed tomography.















































patients in whom S100B values were obtained (median of three
samples per subject).
Graphical displays
Graphical representation of biomarker levels during the first
24 h are shown. Figures 2A, 2B, and 2C are scatter plots and
Figures 3A, 3B, and 3C are spaghetti plots all with the LOESS
regression lines demonstrating biomarker values (please note
the different concentrations scales for each biomarker). The
figures suggest that UCH-L1 levels were elevated early but
began to slowly decline after 12 h, whereas GFAP levels rose a
bit later and remained elevated over the 24-h study time period
and S100B levels seem to decline early. These same figures
suggest that there was variability among patients in the starting
point (intercept) and rate of change (slope) for all three bio-
markers. When comparing the rate of change in serum bio-
marker concentration between CT-positive and CT-negative
patients, there was little obvious difference for UCH-L1 and
S100B, but GFAP concentration rose more rapidly in the CT-
positive population. There were significant correlations in bio-
marker values measured over 24 h for UCH-L1 and S100B,
UCH-L1 and GFAP, and GFAP and S100B (Spearman corre-
lation coefficient 0.77, 0.50, and 0.37, respectively; p < 0.0001
for all three comparisons).
Graphics for each biomarkers’ AUROC curves, paneled by time
intervals, are shown with the AUROC (95% CI) inset within each
(Fig. 4). No formal statistical testing was done but it appears that
GFAP and UCH-L1 perform best in the 6-12 h and 12-18 h post-
injury windows.
Biomarker kinetics model results
The final models included sex, GCS (< 15 vs. 15), time, CT
results, and the CT*Time interaction. Other considered variables
were removed since they exhibited collinearity (such as LOC) or
did not add more information to the models (such as age). Con-
sistent with the graphical display, all three biomarkers were, on
average, higher among CT-positive versus CT-negative patients.
This was true even after accounting for the initial GCS score. Only
GFAP, however, significantly rose over time among CT-positive
patients, compared with CT-negative patients (estimate = 0.036;
95% CI 0.02 to 0.05; p < 0.001). When back transforming the es-
timate of the log of GFAP (e0.03601 = 1.0367), we found that GFAP
concentrations rose by 3.7% (95% CI 2.2% to 5.1%) per hour
among CT-positive patients, compared with CT-negative patients.
Table 7 shows the complete results for the fixed effects for all three
biomarkers. All three biomarker concentrations were, on average,
higher for patients who had a positive head CT, and both GFAP and
FIG. 3A. Spaghetti plot with the locally weighted scatter plot smoothing regression lines demonstrating ubiquitin carboxyl-terminal
hydrolase-L1 (UCH-L1) values. Each thin line of the spaghetti plot represents one patient. CT, computed tomography.















































UCH-L1 (but not S100B) were higher among patients who pre-
sented with a GSC <15. The random effects component analysis for
all biomarkers found there was variation in the intercept and slope
among study patients.
The sensitivity analysis looking at only patients with GCS = 15
demonstrated similar findings. The sensitivity analysis that used
reported values even when below the LOD and LLQ also were
similar, with the exception that UCH-L1 did show an increase over
time in CT-positive patients relative to CT-negative patients (a
CT*Time interaction, estimate 0.028, 95% CI 0.007 to 0.048;
p = 0.01), likely due to the lowering of some values below the LOD
(Table 8). Since the lower 95% confidence interval is close to 0, this
result must be interpreted with caution, does not represent our main
result, and is exploratory in nature.
Discussion
This prospective multi-center observational study evaluated the
usefulness of serial serum concentrations of GFAP, UCH-L1, and
S100B during the initial 24 h after mild-to-moderate traumatic
brain injury to differentiate between patients with an acute injury
on CT and those without. Our results demonstrated that all three
serum biomarker concentrations were, on average, higher in CT-
positive versus CT-negative patients with suspected mmTBI. When
considering serum concentration changes over time, only GFAP
showed a significant increase in CT-positive patients, compared
with CT-negative patients. Among patients with a positive head
CT, GFAP levels rise on average by 3.7% per hour, compared with
suspected mmTBI patients with a negative CT, for which a more
flat trend line was noted, suggesting that GFAP may be a more
useful marker when evaluating these patients. Neither UCH-L1 nor
S100B were found to have a significant difference in rate of change
in CT-positive compared with CT-negative patients. Our data is
applicable to individual patients since random effects modeling
(random intercept and slope) was utilized to account for patient-
level variations in initial biomarker value and differences in
changes over time. These results are consistent with and compli-
mentary to recently published data regarding the time courses of
UCH-L1 and GFAP.20 Additionally, this study graphically de-
scribed and quantitated the kinetics of these biomarkers during the
24-h post-injury period.
While GFAP, UCH-L1, and S100B have all been studied in
mmTBI, only limited information about the temporal profiles of
these circulating biomarkers is available. Therefore, we conducted
one of the first studies designed to repeatedly measure GFAP,
UCH-L1, and S100B in the same patient cohort, with the goal of
further characterizing differences in the biomarkers’ kinetics
among CT-positive and CT-negative patients. The biomarkers’
FIG. 3B. Spaghetti plots with the locally weighted scatter plot smoothing regression lines demonstrating glial fibrillary acidic protein
(GFAP) values. Each thin line of the spaghetti plot represents one patient. CT, computed tomography.















































diagnostic ability to detect acute intracranial lesions on head CT
scans was compared at approximately 6-h intervals over the course
of 24 h to determine optimal testing strategies for mmTBI in a
clinical setting. Our results suggest that GFAP offers the widest
temporal profile for differentiating between positive and negative
head CT scans, and may therefore be the most robust biomarker to
aid clinicians in identifying patients with acute intracranial lesions
during the initial 24 h after injury.
Consistent with previous reports, the present study found that the
serum concentrations of GFAP, UCH-L1, and S100B were all per-
sistently higher among mmTBI patients with CT-proven intracranial
lesions. While all three biomarkers were detected in the serum of CT-
positive patients within 6 h of mmTBI, only GFAP concentration
continued to increase significantly over the initial 24 h among CT-
positive patients, compared with CT-negative patients. This finding
confirmed, in an independent sample of patients with mmTBI, the
results of Papa and colleagues, who reported serum GFAP levels
peaked 20 h after mmTBI among those with intracranial lesions
detected on CT, and slowly declined over 72 h, leading to better
diagnostic accuracy than UCH-L1 at all time-points.20 As a sup-
plement to our results, the same study compared the performance of
GFAP and UCH-L1 among patients without clinical evidence of
brain injury (trauma controls) and in trauma patients with clinical
evidence of traumatic brain injury over the course of 7 days post-
injury. Significantly higher levels of GFAP and UCH-L1 were found
in patients with mmTBI than in the trauma controls, suggesting that
both GFAP and UCH-L1 are specific for brain injury and not merely
elevated in all patients presenting with trauma.20
Our study also found that UCH-L1 levels were significantly el-
evated early after injury among CT-positive patients, but remained
relatively stable before falling later in the time course and again,
supports other’s data showing that UCH-L1 was detectible in serum
within 1 h of injury, peaked at 8 h, and subsequently decreased over
48 h.20 This early peak in UCH-L1 among those with CT-proven
intracranial lesions also is consistent with our initial study, which
demonstrated UCH-L1 had improved ability to rule out CT findings
when obtained within 6 h of injury, compared with GFAP and
S100B.18 The sensitivity analyses that incorporated reported values
(even when below the LOD and LLQ) did suggest that UCH-L1
may increase over time in CT-positive patients must be interpreted
with caution given that it was exploratory analysis and the previ-
ously described difficulty and less than optimal methods to ‘‘as-
sign’’ values when the results are below the test thresholds.23–26
S100B, although used in some parts of the world,21 was not
found to have a kinetics pattern that would help in the later diag-
nosis or monitoring of patients with mmTBI. Our findings were in
contrast to other work that showed S100B levels rose and peaked at
27.2 h post-injury; however, that study examined more seriously
FIG. 3C. Spaghetti plots with the locally weighted scatter plot smoothing regression lines demonstrating S100B values. Each thin line
of the spaghetti plot represents one patient. CT, computed tomography.















































FIG. 4. Area under the receiver operator characteristic curve (AUC) for each biomarker stratified by 6-h time intervals. CI, confidence
interval; GFAP, glial fibrillary acidic protein; UCH-L1, ubiquitin carboxyl-terminal hydrolase-L1.















































Table 7. Main Models—Natural Log Transformation
UCH-L1 (n = 167) Estimate SE 95% CI p Value % Change
Intercept 4.223 0.099 4.027, 4.418 <0.0001
Female -0.016 0.117 -0.247, 0.214 0.89 -1.6
GCS <15 0.635 0.169 0.301, 0.968 0.0002 88.7
Time -0.043 0.004 -0.051, -0.036 <0.0001 -4.3
Positive CT 0.710 0.195 0.326, 1.094 0.0003 103.4
Positive CT*Time 0.010 0.007 -0.004, 0.024 0.15 1.0
GFAP (n = 167) Estimate SE 95% CI p Value % Change
Intercept 3.420 0.105 3.212, 3.628 <0.0001
Female 0.037 0.146 -0.251, 0.324 0.8 3.8
GCS <15 0.355 0.209 -0.057, 0.767 0.091 42.6
Time 0.004 0.004 -0.004, 0.011 0.37 0.4
Positive CT 1.412 0.193 1.031, 1.793 <0.0001 310.5
Positive CT*Time 0.036 0.007 0.022, 0.050 <0.0001 3.7
S100B (n = 152) Estimate SE 95% CI p Value % Change
Intercept 5.019 0.106 4.810, 5.227 <0.0001
Female 0.089 0.117 -0.144, 0.321 0.45 9.3
GCS <15 0.171 0.170 -0.166, 0.507 0.32 18.6
Time -0.070 0.007 -0.084, -0.057 <0.0001 -6.8
Positive CT 0.600 0.202 0.202, 0.998 0.003 82.2
Positive CT*Time 0.008 0.012 -0.015, 0.032 0.475 0.9
% Change is for listed features relative to other (i.e., having a GCS <15, compared with a GCS = 15, results in a 95.0% change in serum UCH-L1
concentration) except time is for each 1-h increase. Calculated by (Estimate - 1) · 100 using unrounded estimates (rounded estimates presented in Table).
UCH-L1, ubiquitin carboxyl-terminal hydrolase-L1; SE, standard error; CI, confidence interval; GCS, Glasgow Coma Scale; CT, computed
tomography; GFAP, glial fibrillary acidic protein.
Table 8. Sensitivity Analysis
Only GCS = 15 Actual reported values*
Estimate SE 95% CI p Value Estimate SE 95% CI p Value
UCH-L1 (n 5 143) (n 5 167)
Intercept 4.320 0.102 4.119, 4.521 <0.0001 4.155 0.125 3.908, 4.402 <0.0001
Female -0.164 0.118 -0.396, 0.069 0.17 -0.016 0.153 -0.318, 0.286 0.92
GCS <15 0.687 0.221 0.250, 1.123 0.002
Time -0.043 0.004 -0.051, -0.036 <0.0001 -0.063 0.005 -0.074, -0.052 <0.0001
Positive CT 0.505 0.228 0.056, 0.955 0.028 0.746 0.242 0.270, 1.223 0.002
Positive CT*Time 0.009 0.009 -0.008, 0.026 0.30 0.028 0.011 0.007, 0.048 0.01
GFAP
Intercept 3.494 0.107 3.282, 3.707 <0.0001 2.540 0.176 2.193, 2.887 <0.0001
Female -0.019 0.155 -0.324, 0.286 0.90 -0.078 0.237 -0.546, 0.389 0.74
GCS <15 0.591 0.341 -0.081, 1.262 0.084
Time 0.002 0.003 -0.005, 0.008 0.56 0.008 0.006 -0.004, 0.0207 0.19
Positive CT 1.134 0.218 0.704, 1.564 <0.0001 1.959 0.326 1.317, 2.601 <0.0001
Positive CT*Time 0.036 0.007 0.023, 0.050 <0.0001 0.038 0.012 0.016, 0.061 0.001
Estimate SE 95% CI p Value Estimate SE 95% CI p Value
S100B (n 5 130) (n 5 152)
Intercept 5.099 0.111 4.880, 5.318 <0.0001 5.019 0.106 4.810, 5.227 <0.0001
Female -0.005 0.122 -0.247, 0.238 0.97 0.089 0.120 -0.144, 0.321 0.45
GCS <15 0.171 0.170 -0.166, 0.507 0.32
Time -0.072 0.007 -0.085, -0.058 <0.0001 -0.070 0.007 -0.084, -0.057 <0.0001
Positive CT 0.429 0.238 -0.044, 0.901 0.075 0.600 0.202 0.202, 0.998 0.003
Positive CT*Time 0.009 0.013 -0.020, 0.038 0.49 0.008 0.012 -0.015, 0.032 0.47
* This uses reported values even if below the limit of detection; values of zero were recorded to 1 due to need of log transformation.
GCS, Glasgow Coma Scale; UCH-L1, ubiquitin carboxyl-terminal hydrolase-L1; SE, standard error; CI, confidence interval; CT, computed
















































injured patients (median GCS = 7, mortality 9.7%) and may not be a
good comparator.28
Finally, even though the study was not designed to determine the
utility of following biomarkers for pre-clinical studies screening for
potential therapies, clinical progression of injury among patients
with TBI, or as a surrogate outcome, our results suggest that GFAP
may be an ideal candidate for such studies and use.29,30
Limitations
Limitations of the present study include the fact that we lacked
biomarker measurements at every time-point on every patient.
However, with this in mind we chose to analyze our data using a
generalization of mixed linear models, which are designed to handle
missing data without dropping the entire case. There were fewer
patients and measurements of S100B since it was instituted later in
the protocol, making these results less certain. Due to the distribution
of biomarker values, a log transformation was used, despite the fact
that it makes interpretation of the results less intuitive than when
actual non-transformed values are used. This study included patients
with suspected mmTBI and a GCS ranging from 9-15 but our sen-
sitivity analysis confirmed similar results among patients with a
GCS = 15, making our results potentially applicable to the minimally
injured patient. Additionally, this early study’s primary objective
was to evaluate the association between CT findings and serum
biomarker concentrations over time, and therefore it did not assess
patient-centered clinical outcomes, such as the need for neurosur-
gical intervention. This study was not designed to identify those
patients who sustained neuronal injuries in the absence of positive
CT findings nor did the study include patients for whom the treating
clinician determined that a head CT was not warranted (minimal to
no evidence of mmTBI). Finally, the study was not designed to
determine the need for repeat biomarker measurements to follow a
patient’s clinical course but does suggest potential value in doing so.
Conclusion
In conclusion, our data suggest that the diagnostic ability of
UCH-L1 may be limited to the early h after mild-to-moderate TBI,
whereas rising serum GFAP concentrations over the initial 24 h
post-injury were associated with a positive head CT. The longer
half-life and wider temporal profile of GFAP indicates it may be a
more robust biomarker to detect patients with CT-proven intra-
cranial lesions, and although further study is needed, these results
suggest that GFAP levels may be a useful test to follow throughout
a patient’s first 24 h of care.
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